# Sacituzumab Govitecan and Q901 in Advanced TNBC

Source: https://onco.cc/trials/nct07788222/  
OnCo record `nct07788222` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Yonsei University, not yet recruiting.

## Summary

Sacituzumab Govitecan and Q901 in Advanced TNBC is a phase 2, interventional study registered as NCT07788222 by Yonsei University, with a registry enrolment figure of 48 participants, started 2026-09-01 and due to reach its primary completion in 2028-05-31. Interventions recorded: Sacituzumab govitecan and Q901. Conditions listed: Triple Negative Breast Neoplasms. Triple-negative eligibility wording from the registry: "Patients with histologically or cytologically confirmed triple-negative breast cancer (TNBC) who have received at least 2 prior lines of systemic anticancer therapy for recurrent, metastatic, or unresectable disease". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07788222
- Phase: 2
- Setting: Multi-center, Open-label, Single-arm Phase II Clinical Trial of Sacituzumab-Govitecan Plus Q901 in Advanced TNBC
- Sponsor: Yonsei University
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07788222: https://clinicaltrials.gov/study/NCT07788222

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07788222.json